Clinical trial · Observational
Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma
Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior
NCT01824966CI-TRIAL-00009924SRCCcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas. To clarify the biologic behavior of SRCs, the investigators compared the clinicopathologic features and prognosis of SRCs with other adenocarcinomas (ADC) of the esophagus and gastroesophageal junction (GEJ).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- SRC<50%
- description
- Adenocarcinoma containing \< 50% of signet ring cells
- label
- SRC>50%
- description
- Adenocarcinoma containing \> 50% of signet ring cells
Primary outcomes (1)
- measure
- Cancer specific 5 year survival in SRCC
- timeFrame
- from surgery
- description
- Cancer specific 5 year survival classified into two groups according to WHO criteria (\>50% SRC or \<50% SRC)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- Adenocarcinoma R0 resection Primary surgery Exclusion Criteria: \- Other histology R1 or R2 resection Neoadjuvant therapy
References
Publications (0)
Data not yet available
No reference posted for this study.